Skip to content
Screener

MaxCyte MXCT Q2 2026 earnings

Reported August 12, 2026 · After market close

Revenue$7.3MBeat by $764.8K
EPS-$0.08Beat by $0.01
Revenue estimate$6.5M
EPS estimate-$0.09

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$7.0M
EPS estimate-$0.08

Financials

Q2 2026

Income statement

See full
Revenue$7.3M-14.5%
Gross profit$5.6M-19.9%
Operating income-$10.2M+28.1%
Net income-$8.9M+28.2%
EPS (diluted)-$0.08+33.3%

Balance sheet

See full
Cash & equivalents$15.0M-1.2%
Total debt$17.3M-6.8%
Total equity$158.8M-16.8%
Total assets$184.7M-16.0%

Cash flow

See full
Operating cash flow-$4.7M+52.7%
CapEx$62.0K-89.4%
Free cash flow-$4.7M+54.7%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$135.2M-9.4%
Enterprise value$137.41M-9.9%
P/S4.4×+0.2×

Profitability

See full
Gross margin79.2%-0.6pp
Operating margin-134.6%-12.2pp
Net margin-114.8%-8.8pp
FCF margin-76.1%-17.1pp

Returns & leverage

See full
Return on equity-20.4%-1.2pp
Debt / equity0.1×0.0×
Current ratio12.3×-0.1×

Segments

By product

See full
License$2.6M-11.5%
Assay And Other Service Revenue$583.0K+88.1%

By segment

See full
Cell Engineering Technology$7.3M-14.5%

FAQ

When did MaxCyte report Q2 2026 earnings?
MaxCyte (MXCT) reported Q2 2026 earnings on August 12, 2026 after market close.
What were MaxCyte's Q2 2026 revenue and EPS?
MaxCyte reported revenue of $7.3M and eps of $-0.08 for Q2 2026.
Did MaxCyte beat estimates in Q2 2026?
Revenue beat the consensus estimate of $6.5M by $764.8K. EPS beat the consensus estimate of $-0.09 by $0.01.
How did MaxCyte's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 14.5% from $8.5M a year earlier and eps grew 33.3% from $-0.12.
Where can I find MaxCyte's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-094886) and the 10-Q periodic report (0001104659-26-095971) directly on SEC EDGAR. The filing index links above go to sec.gov.